Immunohistochemical overexpression of the p53 protein and Ki-67 (MIB-1) antigen in patients with GERD and chronic esophagitis

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 3, 2010, Pages 236-243

  Binato, Marcelo ^a   Fagundes, Renato ^b   Gurski, Richard ^a   Meurer, Luise ^c   Edelweiss, Maria Isabel ^c  

^a Division of General Surgery   (United States)

^b Division of Gastroenterology   (United States)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Adenocarcinoma; Esophagitis; GERD; Ki 67 (MIB 1); P53

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOPSY; DISEASE PROGRESSION; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; KI-67 ANTIGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77951744150     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181c49134     Document Type: Article

References (49)

1. Voutilainen M, Sipponen P, Mecklin JP, et al. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Dig. 2000;61:6-13.
2. Achem SR. Endoscopy negative gastroesophageal reflux disease. The hypersensitive esophagus. Gastroenterol Clin North Am. 1999; 28:893-904.
3. Moraes-Filho JPP, Cecconello I, Gama-Rodrigues J, et al. Brazilian consensus on gastroesophageal reflux disease: proposals for assessment, classification, and management. Am J Gastroenterol. 2002;97: 241-248.
4. Avidan B, Sonnenberg A, Schnell TG, et al. There are no reliable symptoms for erosive esophagitis and Barrett's oesophagus: endoscopic diagnosis is still essential. Aliment Pharmacol Ther. 2002;16: 735-742.
5. Wetscher GJ, Hinder RA, Kingler P, et al. Reflux esophagitis in humans is a free radical event. Dis Esoph. 1997;10:29-32.
6. Bremner CG, Lynch VP, Ellis HF. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery. 1970;68:209-216.
7. Correa P, Miller MJ. Carcinogenesis, apoptosis and cell proliferation. Br Med Bull. 1998;54:152-162.
8. Manabe N, Yoshihara M, Sasaki A, et al. Reflux esophagitis: natural history and treatment. J Gastroenterol Hepatol. 2002;17:949-954.
9. Solaymani-Dodaran M. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut. 2004;53:1070-1074.
10. Flora-Filho R, Câmara-Lopes LH, Zilberstein B. Critérios histoló - gicos na doença do refluxo gastroesofá gico. Reavaliação da sensibilidade da pHmetria esofá gica de 24 horas. Arq Gastroenterol. 2000;37:1-10.
11. Nishiyama Y, Koyama S, Andoh A, et al. Immunohistochemical analysis of cell cycle-regulating-protein (p21, p27, and Ki-67) expression in gastroesophageal reflux disease. J Gastroenterol. 2002;37: 905-911.
12. Moons LM, Kuster JG, Bultman E, et al. Barrett esophagus is characterized by a predominantly humoral inflammatory response. J Pathol. 2005;207:269-276.
13. O'Riordan JM, Abdel-latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation- metaplasia-dysplasia- adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100:1257-1264.
14. Mandard AM, Marnay J, Lebeau C, et al. Expression p53 in oesophageal squamous epithelium from surgical specimens resected for carcinoma of the esophagus, with special reference to uninvolved mucosa. J Pathol. 1997;181:153-157.
15. Chino O, Kijima H, Shimada H, et al. Clinic pathological studies of esophageal carcinoma in achalasia: analyses of carcinogenesis using histological and immunohistochemical procedures. Anticancer Res. 2000;20:3717-3722.
16. Wang DY, Xiang YY, Tanaka M, et al. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer. 1994;74:3089-3096.
17. Nigro JM, Baker SJ, Preiseinger AC, et al. Mutations in the p53 gene occur in diverse human types. Nature. 1989;342:705-708.
18. Lane DP. p53, guardian of the genome. Nature. 1992;358:15-16.
19. Tjian R. Molecular machines that control genes. Sci Am. 1995;00: 54-61.
20. Krishnadath KK, Tilanus HW, Blankeistein MV, et al. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophageal. J Pathol. 1995;75:175-180.
21. Fagundes RB, Melo CR, Putten AC, et al. p53 immunoexpression: an aid to conventional methods in the screening of precursor lesions of squamous esophageal cancer in patients at high-risk? Cancer Detect Prev. 2005;29:227-232.
22. Casson AG, Mukhopaday T, Cleary KR, et al. P53 gene mutations in Barrett's epithelium and oesophageal cancer. Cancer Res. 1991; 51:4495-4499.
23. Gerdes J, Becker MH, Key G, et al. Immunohistological detection of tumor growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol. 1992;168:85-86.
24. Gerdes J, Lemke H, Braisch H, et al. Cell cycle of a proliferationassociated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;33:1710-1715.
25. Cattoretti G, Becker MH, Key G, et al. J. Monoclonal antibodies against recombinant parts of the ki-67 antigen (MIB-1 and MIB-3) detect proliferation cells in microwave-processed formal in fixed paraffin section. J Pathol. 1992;168:357-363.
26. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172-180.
27. Riddel RH. The biopsy diagnosis of gastroesophageal reflux disease, ''carditis,'' and Barrett's esophagus, and sequel of therapy. Am J Surg Pathol. 1996;20:31-50.
28. Weston AP, Banerjee SK, Sharma P, et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol. 2001;96:1355-1362.
29. Feith M, Stein HJ, Mueller J, et al. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis Esophagus. 2004;17:322-327.
30. Chen X, Ouyang Q, Zhang WY, et al. The clinical, pathological features and expression of Ki-67 and COX-2 in severe reflux esophagitis and Barrett's esophagus. Sichuan Da Xue Boa Yi Xue an. 2005;36:207-209.
31. Hillmann LC, Chiragakis L, Clarke AC, et al. Barrett's esophagus: macroscopic markers and the prediction of dysplasia and adenocarcinoma. J Gastroenterol Hepatol. 2003;18:526-533.
32. Ismail-Beiji F, Horton PF, Pope CE II. Histological consequences of Gastroesophageal reflux in an. Gastroenterol. 1970;58:163-174.
33. Protheroe C, Woodruff SA, de Petris G, et al. A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2009;7:749-755.
34. Wang LD, Hong JY, Qiu SL, et al. Accumulation of P53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res. 1993;53:1783-1787.
35. Wynford-Thomas D. p53 in tumor pathology: can we trust immunoctochemistry? J Pathol. 1992;166:329-330.
36. Segal F, Kaspary AP, Prolla JC, et al. p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett's esophagus. Cancer Let. 2004; 210:213-218.
37. Ribeiro U Jr, Alves VA, Souza PMSB, et al. Correlação das prote? ́nas p53 e Ki-67 com o prognó stico de pacientes com adenocarcinoma de reto distal. Rev Bras Coloproct. 2000;20:248-256.
38. Lopes CV, Pereira-Lima J, Hartmann AA, et al. O critério de positividade para a aná lise imunoistoquímica da p53na confirmação da displasia do esôfago de barrett faz diferença? Ar Gastroenterol. 2005; 42:233-238.
39. Goldman H, Antonioli DA. Mucosal biopsy of the esophagus, stomach, and proximal duodenum. Human Pathol. 1982;13:423-448.
40. Polkowski W, van Lanschot JJ, ten Kate FJ, et al. The value of p53 and Ki-67 as markers for tumor progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol. 1995;4:163-171.
41. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990;17:489-503.
42. Iftikhar SY, Steele RJ, Watson S, et al. Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's oesophagus. Gut. 1992;33:733-737.
43. Ribeiro AVS, Ribeiro U, Sakai P, et al. Integrated p53 histopathologic/ genetic analysis of premalignant lesions of the esophagus. Cancer Detect Prev. 2000;24:13-23.
44. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-displasia-adenocarcinoma sequence in the esophagus. Am J Pathol. 1999;154:965-973.
45. Ohbu M, Kobayashi N, Okayasu I. Expression of cell cycle regulatory proteins in the multistep process of oesophageal carcinogenesis: stepwise over-expression of cyclin E and p53, reduction of p21 (WAF1/CIP1) and deregulation of cyclin D1 and p27(KIP1). Histopathol. 2001;39:589-596.
46. Fujiwara Y, Higuchi K, Hamaguchi M, et al. Increased expression of transformation growth factor-alpha and epidermal growth factor receptors in rat chronic reflux esophagitis. J Gastroenterol Hepatol. 2004;19:521-527.
47. Boni L, Benevento A, Shimi SMS, et al. Free radical production in the esophago-gastro-duodenal mucosa in response to acid and bile. Dis Esophagus. 2006;19:99-104.
48. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut. 2002;50:451-459.
49. Farhadi A, Fields J, Banan A, et al. Reactive oxygen species: are they involved in the pathogenesis of GERD, Barrett's esophagus, and the latter's progression toward esophageal cancer? Am J Gastroenterol. 2002;97:22-26.